Skip to content
Screener

Common Stock at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
300M0.0%
ALN
Alnylam PharmaceuticalsALNY
250M0.0%
Assembly Biosciences logo
Assembly BiosciencesASMB
$16K+100%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$1.44B+2.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0-100%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$1.03M+2.1%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemMarch 31, 2026September 30, 2025
Total long-term liabilities1,374,129686,392
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value:Authorized 290,000 shares; 143,232 shares issued and 140,571 outstanding as of March 31, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025236231
Additional paid-in capital2,395,2672,139,725
Accumulated other comprehensive income7426,443
Accumulated deficit(1,729,075)(1,627,154)
Treasury stock; at cost; 2,661 shares of common stock at March 31, 2026 and September 30, 2025(53,193)(53,193)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's common stock?
Arrowhead Research (ARWR) reported common stock of $236K in Q1 2026.
How has Arrowhead Research's common stock changed year-over-year?
Arrowhead Research's common stock increased by 2.6% year-over-year, from $230K to $236K.
What is the long-term trend for Arrowhead Research's common stock?
Over 4 years (2021 to 2025), Arrowhead Research's common stock has grown at a 4.1% compound annual growth rate (CAGR), from $197K to $231K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Arrowhead Research's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude